San Diego-dependent Viking Therapeutics marked alone as a significant competitor within the weight loss drug industry in February following revealing promising info from a mid-phase trial of experimental drug VK2735, which proposed it rivaled—and outperformed—Novo and Lilly drugs when specified as a weekly injection and in March the company unv